Chimeric antigen receptor (CAR) targeting CD37 and anticancer application thereof

By designing a chimeric antigen receptor CAR targeting CD37, combining the IL-21 domain, the self-cancer and persistence of CAR-T cell therapy in the treatment of T cell malignant tumors was solved, and the T cell malignant tumors was achieved. Effective inhibition and improvement of anti-tumor activity.

CN119080947AActive Publication Date: 2024-12-06HUANGSHAN YONGSHENG TRIBE STEM CELL TECHNOLOGY CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411209636.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-12-06
Estimated Expiration
2044-08-30

AI Technical Summary

Technical Problem

The existing CAR-T cell therapy faces the problem of self-killing when treating T cell malignant tumors. The preparation process is complex and costly. There is little research on CD37 as a new target. It is difficult to produce sustainable therapeutic effects for CD28 costimulation, which affects the anti-tumor effect. .

Method used

A chimeric antigen receptor CAR targeting CD37 was designed, including signal peptide, anti CD37 scFv, hinge region, transmembrane region, costimulator CD28 and CD3ζ signal domain, and the IL-21 domain was introduced to optimize the CAR structure. To improve anti-tumor activity and inhibit T cell failure.

Benefits of technology

The CAR-T cells can effectively identify and inhibit tumor cell growth, reduce self-killing events, improve anti-tumor activity and durability, significantly prolong animal survival, and effectively exert anti-tumor effects in vivo and in vitro.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080947A_ABST
    Figure CN119080947A_ABST
Patent Text Reader

Abstract

The invention provides a CD37-targeting chimeric antigen receptor (CAR) and anticancer application thereof, the chimeric antigen receptor comprises a signal peptide, an anti CD37scFv, a hinge region, a transmembrane region, a costimulatory factor and a CD3 zeta signal domain, the anti CD37scFv comprises a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 1 and a light chain variable region with an amino acid sequence as shown in SEQ ID NO: 2, the anti CD37scFv can effectively recognize a target antigen, and the anti CD37scFv can effectively recognize the target antigen. And humanized transformation is carried out. Furthermore, the chimeric antigen receptor further comprises an IL-21 structural domain. The CAR-T cell provided by the invention can effectively inhibit the growth of tumor cells in vivo and in vitro, and provides a basis for the development of related drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology research and development, and specifically provides a chimeric antigen receptor (CAR) targeting CD37 and its anti-cancer use. Background Art

[0002] Since its initial approval by the U.S. Food and Drug Administration (FDA) in 2017, chimeric antigen receptor (CAR)-T cell therapy has become a mainstay in the treatment of B-cell malignancies, including leukemias, lymphomas, and multiple myeloma (MM). To date, six products targeting CD19 or B cell maturation antigen (BCMA) have been approved in the United States (see Cappell, KM, and Kochenderfer JN Long-term outcomes following CAR T cell therapy: What we know so far. Nat. Rev. Clin. Oncol. 2023, 20: 359–371), and a large number of ongoing trials are evaluating other candidate drugs for hematological malignancies and solid tumors (see Wang, X., and Rivière I.. Manufacturing of CAR-T cells: The assembly line. In Gene and Cellular Immunotherapy for Cancer. Ghobadi A., and DiPersio JF, editor. Humana, Cham, Switzerland. 2022, 121–139). In addition, CD19 CAR-T cell therapy has recently been applied to treat autoimmune diseases, and early data show encouraging results in patients with systemic lupus erythematosus (see Mackensen, A., Müller F., Mougiakakos D., et al. Anti-CD19 CAR T cell therapy for refractory systemiclupus erythematosus. Nat. Med. 2022, 28: 2124–2132)

[0003] Compared with B-cell malignancies, T-cell malignancies are also common blood tumors in clinical practice, among which T-cell acute lymphoblastic leukemia (T-ALL) accounts for about 25% of adult ALL and 10-15% of childhood ALL. T-ALL originates from the leukemic transformation of thymic progenitor cells through the accumulation of genetic abnormalities during T-cell development. Over the past three decades, significant progress has been made in the treatment of ALL (including T-ALL), and the overall survival rate has continued to improve, especially in children under 15 years old. However, the survival rate of adult T-ALL patients is significantly lower than that of children and young people, and the prognosis of patients with relapsed / refractory disease is poor, with a survival rate of 10-25% (see DuVall AS, Sheade J, Anderson D, et al. Updates in the management of relapsed and refractory acute lymphoblastic leukemia: an urgent plea for new treatment inbeing answered. JCO Oncol Pract. 2022, 18: 479–487). CAR-T cell therapy has achieved considerable success in the treatment of B-cell malignancies. These advances in the treatment of a variety of hematological malignancies have triggered the exploration of CAR-T cell therapy in T-cell malignancies. However, extending CAR-T cell therapy to T-cell malignancies is particularly challenging due to the co-expression of many cell membrane antigen targets between normal cells and malignant cells (see Liu J, Zhang Y, Guo R, et al. Targeted CD7 CAR T-cells for treatment of T-lymphocte leukemia and lymphoma and acute myeloid leukemia: recent advances. Fron Immunol. 2023, 14: 1170968).

[0004] Therefore, the selection of anti-tumor targets is crucial for T cell tumor treatment. Common targets include CD7, CD5, etc. However, since CD7 and CD5 are expressed on normal T lymphocytes and NK cells, uninhibited CD7 expression on the cell membrane of T lymphocytes will lead to fratricide, so it is necessary to block the expression of related genes on the T cell membrane, such as gene editing, protein blockers and natural selection. For example, knocking out the CD7 gene using the CRISPR / CAS9 gene editing system can prevent fratricide and exert specific anti-tumor activity against malignant T leukemia cells (see Gomes-Silva D, Srinivasan M, Sharma S, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017, 130: 285–296); Wong et al. used a CD7 protein blocker to develop an anti-CD7 CAR-T cell (PCART7) in which both CD7 and CD3 expression were depleted. The cell exhibited strong cytotoxicity against T-ALL and T lymphoma cells. The protein blocker consists of a single-chain variable fragment and an intracellular retention domain, which anchors the target antigen in the endoplasmic reticulum and Golgi apparatus before proteolytic degradation, and can downregulate CD7 expression in T cells without CD7 gene editing (see Wong XFA, Ng J, Zheng S, et al. Development of an off-the-Sh elfchimeric antigen receptor (CAR)-T cell therapy for T-cell acute lymphoblasticleukemia (T-ALL) without gene editing. Blood. 2022, 140 (suppl 1): 2358–2359).

[0005] Although the above method can obtain CAR-T cells that can effectively treat T cell malignancies, it requires a complex method to block the expression of the target protein on the T cell membrane. The preparation process is too cumbersome, the production cost is greatly increased, and it is not conducive to clinical use, which greatly reduces the therapeutic effect. Compared with CD7 and CD5, CD37 is a recently discovered therapeutic target for the treatment of T cell malignancies. It is a transmembrane protein of the tetraspanin superfamily. Some T cell lymphomas express CD37 on their cell membranes. No significant fratricidal-related events were observed during the use of CAR-T targeting CD37 (see Chun I, Kim KH, Chiang YH, et al. CRISPR-Cas9 knock out of CD5 enhances the antitumor activity of chiemeric antigen receptor T cells. Blood. 2020, 136 (suppl 1): 51–52.), so it is expected to become an effective therapeutic target for T cell malignancies. However, there are currently few studies on CD37 CAT-T cells, and only one study has entered the clinical trial stage (NCT 04136275), involving hematological malignancies, including leukemia, B cell and T cell lymphomas (see Frigault MJ, Chen YB, Gallagher K, et al. Phase 1 study of CD37-directed CAR T cells in patients with relapsed or refractory CD37+ hematologic malignancies. Blood. 2021, 138(suppl 1): 653).

[0006] In view of this, the present invention has developed a CAR-T cell targeting CD37 and its application in the preparation of anti-tumor drugs, which can effectively identify target cells, prevent CAR-T cells from attacking each other, and effectively inhibit the growth of tumor cells.

[0007] T cell activation is critical to the success of the cell manufacturing process because it directly affects the efficiency of CAR transgene integration and T cell expansion during in vitro culture. The most common method of T cell activation is through CD3 and CD28 stimulation combined with cytokine support. CD3 signaling (signal 1) triggers T cell activation, while CD28 signaling provides the necessary co-stimulation (signal 2) to avoid ineffective immune cells. However, it has been found in clinical practice that CD28 co-stimulation is difficult to produce sustained therapeutic effects, and CAR-T is rapidly metabolized and cleared in the body, which is not conducive to the anti-tumor effect. It may also lead to tumor recurrence and other phenomena, limiting the clinical application of CAR-T cells.

[0008] In view of some shortcomings and deficiencies of CAR-T targeting CD37, the present invention obtains a scFv structure targeting CD37 with higher affinity, and transforms the CAR structure to introduce the IL-21 domain, which can enhance the anti-tumor activity of CAR-T cells, inhibit T cell exhaustion, and effectively treat tumor diseases. Summary of the invention

[0009] The first aspect of the present invention provides a chimeric antigen receptor CAR targeting CD37, wherein the chimeric antigen receptor comprises a signal peptide, an anti CD37 scFv, a hinge region, a transmembrane region, a co-stimulatory factor and a CD3ζ signaling domain, and the anti CD37 scFv comprises a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO: 1 and a light chain variable region having an amino acid sequence as shown in SEQ ID NO: 2.

[0010] Furthermore, the amino acid sequence of the signal peptide is shown in SEQ ID NO:3.

[0011] Furthermore, the co-stimulatory factor is CD28, and its amino acid sequence is shown in SEQ ID NO:6.

[0012] Furthermore, the amino acid sequence of the chimeric antigen receptor is shown in SEQ ID NO:8.

[0013] Furthermore, the chimeric antigen receptor also includes an IL-21 domain, and the amino acid sequence of the IL-21 is shown in SEQ ID NO:9.

[0014] Furthermore, the amino acid sequence of the chimeric antigen receptor is shown in SEQ ID NO:10.

[0015] A second aspect of the present invention provides a CAR-T cell, wherein the CAR-T cell expresses the chimeric antigen receptor.

[0016] The third aspect of the present invention provides a use of the chimeric antigen receptor and / or the CAR-T cell in the preparation of a drug for treating tumors.

[0017] Furthermore, the tumor is a T-cell malignancy.

[0018] Furthermore, the tumor is T-cell acute lymphoblastic leukemia (T-ALL).

[0019] Beneficial Effects

[0020] The present invention provides a chimeric antigen receptor (CAR) targeting CD37 and its anti-cancer use, with the following specific beneficial effects:

[0021] (1) CD37 was selected as the target for constructing CAR, and anti-CD37scFv with a new amino acid structure was provided, which could target and recognize the target antigen;

[0022] (2) The antigen binding domain has been humanized to reduce the inhibitory anti-host response and maintain a longer cell activation time;

[0023] (3) Adding the IL-21 domain to the CAR structure can effectively maintain the activation state of T cells;

[0024] (4) The CAR-T cells provided by the present invention can effectively inhibit the growth of tumor cells both in vivo and in vitro. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 : Schematic diagram of CAR structure;

[0026] Figure 2 : In vitro tumor killing ability of CAR-T cells;

[0027] Figure 3 : Survival of tumor animal models;

[0028] Figure 4 :IFN-γ secretion level in tumor animal models;

[0029] Figure 5 :IL-2 secretion levels in tumor animal models. DETAILED DESCRIPTION

[0030] The experimental methods described in the following examples are conventional methods unless otherwise specified; the reagents, biological materials, and detection kits are all commercially available unless otherwise specified.

[0031] Example 1 Preparation of CAR-T cells

[0032] 1.1 Obtaining the antigen binding domain targeting CD37

[0033] Mice were immunized with recombinant CD37 protein to screen monoclonal antibodies targeting CD37. After obtaining the monoclonal antibody, humanization was performed, and the corresponding CDR region was placed in the humanized antibody framework to obtain a humanized antibody. The amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO: 1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 2. It was determined that the antibody had a high affinity with the target antigen, and the KD value could reach 5.16nM. Studies have shown that humanized scFv can optimize the lifespan of CAR-T cells after infusion, and has advantages in affinity, sensitivity and specificity (see Pouya SK, Pooria SK, Roddy SO, Humanized Chimeric Antigen Receptor (CAR) Tcells, J Cancer Immunol (Wilmington). 2021, 3 (4): 183–187.). Therefore, the use of humanized scFv to construct CAR-T cells in this application can improve the persistence of CAR-T cells and facilitate the sustained anti-tumor effect.

[0034] 1.2 CAR structural design

[0035] The present invention utilizes the second-generation CAR-T structure to construct a chimeric antigen receptor targeting CD37, and its structure is as follows: Figure 1 A, including a signal peptide, a scFv targeting CD37, a hinge region, a transmembrane region, CD28 and CD3ζ domains, wherein the amino acid sequence of the signal peptide is shown in SEQ ID NO: 3, the amino acid sequence of the hinge region is shown in SEQ ID NO: 4, the amino acid sequence of the transmembrane region is shown in SEQ ID NO: 5, the amino acid sequence of CD28 is shown in SEQ ID NO: 6, the amino acid sequence of CD3ζ is shown in SEQ ID NO: 7, and the amino acid sequence of CAR-A is shown in SEQ ID NO: 8.

[0036] In the present invention, CD28 is selected as a co-stimulatory factor to activate T cells. Although it has a strong T cell activation effect, it has also been reported that CD28 can induce T cell apoptosis, thereby affecting the persistence of CAR-T. In this regard, the present invention attempts to introduce IL-21 into the CAR structure. It is reported that IL-21 can enhance the expansion of CART cells after antigen stimulation, reduce the apoptosis level of CART cells during co-culture with tumor cells, and prevent CART cells from differentiating into a late memory phenotype (see Pavlína P,Martin M,et al.Inducible secretion of IL-21augments anti-tumor activity of piggyBac-manufactured chimeric antigen receptor T cells,Cytotherapy.2020,22(12):744-754). CARs with increased IL-21 domains such as Figure 1 B, wherein the amino acid sequence of IL-21 is shown in SEQ ID NO:9, and the amino acid sequence of CAR-B is shown in SEQ ID NO:10.

[0037] 1.3 CAR-T cell preparation

[0038] By means of genetic engineering, the nucleotide sequences encoding CAR-A and CAR-B were cloned into KIRS2 / DAP12-BB and BBζ in the lentiviral backbone to construct a lentiviral expression vector. The nucleic acid sequence was correct after sequencing. 293T cells were cultured at 37°C and 5% CO2 to the logarithmic growth phase, and the lentiviral expression vector carrying the CAR gene and three packaging plasmids were transfected into 293T cells by PEI. After 6 hours of transfection, the medium was changed, and the virus suspension was collected at 24 hours and 48 hours, respectively. Cell debris was removed by 0.45μm membrane filtration, and the virus was collected by centrifugation at 4°C and 12000rpm for 2-4 hours. The precipitate was resuspended in culture medium and stored in a -80°C refrigerator.

[0039] Peripheral blood mononuclear cells were extracted by lymphocyte separation fluid, CD3+ / CD28+T cells were sorted by magnetic beads, and the T cells were cultured in complete culture medium containing (10% FBS and 100IU / mL IL-2). After 24 hours, the slow virus carrying the CAR gene was added at a ratio of MOI=10, and cultured at 37°C and 5% CO2. The medium was changed every 1-2 days for a total of 7-8 days. It was identified that the cells can stably express the target gene and are named CAR-T A and CAR-T B cells.

[0040] Example 2 CAR-T cells inhibit ALL tumor cell proliferation

[0041] This example detects the killing effect of the CAR-T cells on the T-ALL cell line CCRF-CEM and investigates the anti-tumor ability in vitro. CCRF-CEM cells were cultured with DMEM medium containing 10% FBS. After the cells grew to the logarithmic phase, the cells were digested, collected by centrifugation, and inoculated in a 96-well plate after adjusting the cell density. Each well was inoculated with 1×10 4cells, and then added CAR-T A and CAR-T B cells at effector-target ratios (E:T) of 1:1, 1:5, and 1:10, respectively. After culturing at 37°C and 5% CO2 for 24 h, the tumor cell killing rate was detected using an LDH kit (purchased from Biotech Biotechnology Co., Ltd.).

[0042] Cell killing rate = (OD value of experimental calibration well - OD value of effector cell spontaneous calibration well - OD value of target cell spontaneous calibration well) / (OD value of target cell maximum release calibration well - OD value of target cell spontaneous calibration well) × 100%

[0043] The results are shown in Figure 2. The CAR-T provided in the present invention can effectively inhibit the growth of tumor cells and show a significant dose-dependency. Relatively speaking, the killing ability of CAR-T B is stronger than that of CAR-T A, indicating that IL-21 can maintain the activation state of CAR-T cells and contribute to the sustained anti-tumor effect.

[0044] Example 3 CAR-T cells inhibit tumor growth in animals

[0045] 3.1 Preparation of tumor animal model

[0046] 5-8 week old NCG mice were taken and fed adaptively in an SPF environment for 1 week. During this period, CCRF-CEM cells were revived and cultured. When the cell confluence reached 80-90%, subculture was performed, the cells were digested with trypsin, and then resuspended in sterile PBS to adjust the cell density to 1×10 7 100 μL of cell suspension was injected subcutaneously into the tumor-bearing part of the mouse, and the tumor volume was measured every day using a vernier caliper. When the tumor volume reached 100 mm 3 for subsequent experiments.

[0047] 3.2 Drug treatment and animal survival rate observation

[0048] The mice with successful modeling were randomly divided into three groups, with 10 mice in each group: CAR-T group A, intravenously injected with 1×10 6 CAR-T A cells; CAR-T B group, intravenous injection of 1×10 6 CAR-T B cells; control group: intravenous injection of an equal amount of normal saline. The animal status was observed and recorded daily, and the survival curve was drawn using GraphPad Prism 8 software.

[0049] The results are as follows Figure 3As shown in the data, treatment with CAR-T A and CAR-T B cells can significantly prolong the survival of animals, indicating that the CAR-T cells provided by the present invention can effectively exert anti-tumor effects in vivo, and the CAR-T B introduced with IL-21 seems to have a more significant therapeutic effect.

[0050] 3.3 Determination of cytokines in animals

[0051] After 2 weeks of administration, blood was collected from the experimental animals and the plasma was separated by centrifugation. The expression levels of IFN-γ and IL-2 in the plasma were detected using ELISA kits (purchased from Abcam, USA). The specific detection method was carried out according to the instructions of the kits.

[0052] The results are as follows Figure 4 , Figure 5 As shown in the figure, during CAR-T cell therapy, the expression levels of cytokines such as IFN-γ and IL-2 are significantly increased, which can effectively activate immune cells in the body to play an anti-tumor role. In addition, during CAR-T B therapy, the release level of cytokines is higher, especially in promoting IFN-γ secretion, which is significantly stronger than CAR-T A cells without IL-21 domain.

[0053] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that the technical solutions described in the above embodiments may still be modified, or some or all of the technical features may be replaced by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A chimeric antigen receptor CAR targeting CD37, characterized in that: The chimeric antigen receptor includes a signal peptide, an anti CD37 scFv, a hinge region, a transmembrane region, a co-stimulatory factor and a CD3ζ signal domain, and the anti CD37 scFv includes a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 1 and a light chain variable region with an amino acid sequence as shown in SEQ ID NO:

2.

2. The chimeric antigen receptor according to claim 1, characterized in that The amino acid sequence of the signal peptide is shown in SEQ ID NO:

3.

3. The chimeric antigen receptor according to claim 1, characterized in that The co-stimulatory factor is CD28, and its amino acid sequence is shown in SEQ ID NO:

6.

4. The chimeric antigen receptor according to claim 3, characterized in that The amino acid sequence of the chimeric antigen receptor is shown in SEQ ID NO:

8.

5. The chimeric antigen receptor according to any one of claims 1 to 3, characterized in that The chimeric antigen receptor also includes an IL-21 domain, and the amino acid sequence of the IL-21 is shown in SEQ ID NO:

9.

6. The chimeric antigen receptor according to claim 5, characterized in that The amino acid sequence of the chimeric antigen receptor is shown in SEQ ID NO:

10.

7. A CAR-T cell, characterized in that: The CAR-T cell expresses the chimeric antigen receptor according to any one of claims 1-6.

8. Use of the chimeric antigen receptor according to any one of claims 1 to 6 and / or the CAR-T cell according to claim 7 in the preparation of a drug for treating tumors.

9. The use according to claim 10, characterized in that: The tumor is a T-cell malignancy.

10. The use according to claim 10, characterized in that: The tumor is T-cell acute lymphoblastic leukemia T-ALL.

Citation Information

Patent Citations

  • Chimeric antigen receptors targeting CD37

    CN110461363A

  • CD37 antibody and CD37-CAR-T cell

    CN113271965A

  • Humanized CD37 and bi-specific CD19-humanized CD37 CAR-T cells

    CN113980130A